@prefix this: . @prefix sub: . @prefix np: . @prefix dct: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix nkg: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "brovana inhalation solution is a long acting beta 2 2 long term twice daily morning and evening administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema 1 1 important limitations of use brovana inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease 1 2 5 2 brovana inhalation solution is not indicated to treat asthma 1 2 brovana arformoterol tartrate inhalation solution is indicated for the long term twice daily morning and evening maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and emphysema brovana inhalation solution is for use by nebulization only brovana inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease see warnings and precautions 5 2 brovana inhalation solution is not indicated to treat asthma the safety and effectiveness of brovana inhalation solution in asthma have not been established"; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:provided_by ; bl:relation nkg:SymptomaticReliefIndication . bl:category bl:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "SXanaorpvFl3Y6REgLcJHPLZNLq21w1Bi3V0X+LRHf/DjHGvaVk3ghanKEWOj00Hc1ud6xEBbJDrR2D0vCWG/ZtllDebmAYH548FioXERAeaSrIaCoav8vLXeoyG6OP60Qud6BpSBSRq8xDz5nt8u/WVw/+IEL5aNdFumc8NQSw="; npx:hasSignatureTarget this: . this: dct:created "2021-06-12T13:24:21.725+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }